#BEGIN_DRUGCARD DB00205

# AHFS_Codes:
08:30.08

# ATC_Codes:
P01BD01

# Absorption:
Well absorbed with peak levels occurring between 2 to 6 hours following administration

# Biotransformation:
Hepatic

# Brand_Mixtures:
Fansidar Tablets (Pyrimethamine + Sulfadoxine)
Quinnoxine-S (Pyrimethamine + Sulfaquinoxaline)
Sulfaquinoxaline-S Liq (Pyrimethamine + Sulfaquinoxaline)

# Brand_Names:
Darachlor
Daraclor
Darapram
Daraprim
Daraprime
Disulone
Erbaprelina
Fansidar
Khloridin
Malacid
Malocid
Malocide
Maloprim
Pirimecidan
Tindurin
Tinduring

# CAS_Registry_Number:
58-14-0

# ChEBI_ID:
8673

# Chemical_Formula:
C12H13ClN4

# Chemical_IUPAC_Name:
5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
4774

# Description:
One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis. [PubChem]

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Antimalarials
Antiprotozoal Agents
Antiprotozoals
Folic Acid Antagonists

# Drug_Interactions:
Artemether	Pyrimethamine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
Lumefantrine	Pyrimethamine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
Tamoxifen	Pyrimethamine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
Tamsulosin	Pyrimethamine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Pyrimethamine is initiated, discontinued, or dose changed.
Tramadol	Pyrimethamine may decrease the effect of Tramadol by decreasing active metabolite production.

# Drug_Reference:
14711307	Sirichaiwat C, Intaraudom C, Kamchonwongpaisan S, Vanichtanankul J, Thebtaranonth Y, Yuthavong Y: Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum. J Med Chem. 2004 Jan 15;47(2):345-54.
15155209	Gatton ML, Martin LB, Cheng Q: Evolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum. Antimicrob Agents Chemother. 2004 Jun;48(6):2116-23.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
2.69

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
121 mg/L

# Food_Interactions:
Folic acid needs increased.
Take with food to reduce irritation.

# GenBank_ID:
Not Available

# Generic_Name:
Pyrimethamine

# HET_ID:
CP6

# Half_Life:
96 hours

# InChI_Identifier:
InChI=1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17)

# InChI_Key:
InChIKey=WKSAUQYGYAYLPV-UHFFFAOYSA-N

# Indication:
For the treatment of toxoplasmosis and acute malaria; For the prevention of malaria in areas non-resistant to pyrimethamine

# KEGG_Compound_ID:
C07391

# KEGG_Drug_ID:
D00488

# LIMS_Drug_ID:
205

# Mechanism_Of_Action:
Pyrimethamine inhibits the dihydrofolate reductase of plasmodia and thereby blocks the biosynthesis of purines and pyrimidines, which are essential for DNA synthesis and cell multiplication. This leads to failure of nuclear division at the time of schizont formation in erythrocytes and liver.

# Melting_Point:
233.5 °C

# Molecular_Weight_Avg:
248.711

# Molecular_Weight_Mono:
248.082874143

# Organisms_Affected:
Plasmodium

# PDB_Experimental_ID:
1MVT

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451193

# Pharmacology:
Pyrimethamine is an antiparasitic compound commonly used as an adjunct in the treatment of uncomplicated, chloroquine resistant, P. falciparum malaria. Pyrimethamine is a folic acid antagonist and the rationale for its therapeutic action is based on the differential requirement between host and parasite for nucleic acid precursors involved in growth. This activity is highly selective against plasmodia and Toxoplasma gondii. Pyrimethamine possesses blood schizonticidal and some tissue schizonticidal activity against malaria parasites of humans. However, the 4-amino-quinoline compounds are more effective against the erythrocytic schizonts. It does not destroy gametocytes, but arrests sporogony in the mosquito. The action of pyrimethamine against Toxoplasma gondii is greatly enhanced when used in conjunction with sulfonamides.

# Predicted_LogP_Hydrophobicity:
2.62

# Predicted_LogS:
-3.1

# Predicted_Water_Solubility:
1.79e-01 g/l

# Primary_Accession_No:
DB00205

# Protein_Binding:
87%

# PubChem_Compound_ID:
4993

# PubChem_Substance_ID:
46505987

# RxList_Link:
http://www.rxlist.com/cgi/generic/pyrime.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00599

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
CD
Chloridin
Chloridine
Chloridyn
Diaminopyritamin
Ethylpyrimidine
Pirimetamin
Pirimetamina
Primethamine
Pyremethamine
Pyrimethamin
Pyrimethamine Hcl

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:10 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Pyrimethamine

# pKa_Isoelectric_Point:
7.34 (at 20 °C)

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2D6

# Phase_1_Metabolizing_Enzyme_1_ID:
4119

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2D6

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P10635

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP2C9

# Phase_1_Metabolizing_Enzyme_2_ID:
4757

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 2C9

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P11712

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP2C8

# Phase_1_Metabolizing_Enzyme_3_ID:
4924

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 2C8

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 2C8
MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P10632

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
12951104	Rastelli G, Pacchioni S, Parenti MD: Structure of Plasmodium vivax dihydrofolate reductase determined by homology modeling and molecular dynamics refinement. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3257-60.
9108546	Wooden JM, Hartwell LH, Vasquez B, Sibley CH: Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum. Mol Biochem Parasitol. 1997 Mar;85(1):25-40.
9380737	Fidock DA, Wellems TE: Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10931-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
DHFR

# Drug_Target_1_GenBank_ID_Gene:
J00140

# Drug_Target_1_GenBank_ID_Protein:
182724

# Drug_Target_1_GeneCard_ID:
DHFR

# Drug_Target_1_Gene_Name:
DHFR

# Drug_Target_1_Gene_Sequence:
>564 bp
ATGGTTGGTTCGCTAAACTGCATCGTCGCTGTGTCCCAGAACATGGGCATCGGCAAGAAC
GGGGACCTGCCCTGGCCACCGCTCAGGAATGAATTCAGATATTTCCAGAGAATGACCACA
ACCTCTTCAGTAGAAGGTAAACAGAATCTGGTGATTATGGGTAAGAAGACCTGGTTCTCC
ATTCCTGAGAAGAATCGACCTTTAAAGGGTAGAATTAATTTAGTTCTCAGCAGAGAACTC
AAGGAACCTCCACAAGGAGCTCATTTTCTTTCCAGAAGTCTAGATGATGCCTTAAAACTT
ACTGAACAACCAGAATTAGCAAATAAAGTAGACATGGTCTGGATAGTTGGTGGCAGTTCT
GTTTATAAGGAAGCCATGAATCACCCAGGCCATCTTAAACTATTTGTGACAAGGATCATG
CAAGACTTTGAAAGTGACACGTTTTTTCCAGAAATTGATTTGGAGAAATATAAACTTCTG
CCAGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGAGAAAGGCATTAAGTACAAATTT
GAAGTATATGAGAAGAATGATTAA

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
1731871	Stockman BJ, Nirmala NR, Wagner G, Delcamp TJ, DeYarman MT, Freisheim JH: Sequence-specific 1H and 15N resonance assignments for human dihydrofolate reductase in solution. Biochemistry. 1992 Jan 14;31(1):218-29.
2248959	Davies JF 2nd, Delcamp TJ, Prendergast NJ, Ashford VA, Freisheim JH, Kraut J: Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate. Biochemistry. 1990 Oct 9;29(40):9467-79.
3383852	Oefner C, D'Arcy A, Winkler FK: Crystal structure of human dihydrofolate reductase complexed with folate. Eur J Biochem. 1988 Jun 1;174(2):377-85.
6235374	Yang JK, Masters JN, Attardi G: Human dihydrofolate reductase gene organization. Extensive conservation of the G + C-rich 5' non-coding sequence and strong intron size divergence from homologous mammalian genes. J Mol Biol. 1984 Jun 25;176(2):169-87.
6323448	Chen MJ, Shimada T, Moulton AD, Cline A, Humphries RK, Maizel J, Nienhuis AW: The functional human dihydrofolate reductase gene. J Biol Chem. 1984 Mar 25;259(6):3933-43.
6687716	Masters JN, Attardi G: The nucleotide sequence of the cDNA coding for the human dihydrofolic acid reductase. Gene. 1983 Jan-Feb;21(1-2):59-63.
9374868	Cody V, Galitsky N, Luft JR, Pangborn W, Rosowsky A, Blakley RL: Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes reduced with nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523. Biochemistry. 1997 Nov 11;36(45):13897-903.

# Drug_Target_1_HGNC_ID:
HGNC:2861

# Drug_Target_1_HPRD_ID:
00519

# Drug_Target_1_ID:
365

# Drug_Target_1_Locus:
5q11.2-q13.2

# Drug_Target_1_Molecular_Weight:
21322

# Drug_Target_1_Name:
Dihydrofolate reductase

# Drug_Target_1_Number_of_Residues:
186

# Drug_Target_1_PDB_ID:
1MVT

# Drug_Target_1_Pathway:
Methotrexate Pathway	SMP00432

# Drug_Target_1_Pfam_Domain_Function:
PF00186	DHFR_1

# Drug_Target_1_Protein_Sequence:
>Dihydrofolate reductase
VGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSI
PEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSV
YKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFE
VYEKND

# Drug_Target_1_Reaction:
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P00374

# Drug_Target_1_SwissProt_Name:
DYR_HUMAN

# Drug_Target_1_Synonyms:
EC 1.5.1.3

# Drug_Target_1_Theoretical_pI:
7.60

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11964483	Zhang K, Rathod PK: Divergent regulation of dihydrofolate reductase between malaria parasite and human host. Science. 2002 Apr 19;296(5567):545-7.
14622418	Fohl LM, Roos DS: Fitness effects of DHFR-TS mutations associated with pyrimethamine resistance in apicomplexan parasites. Mol Microbiol. 2003 Nov;50(4):1319-27.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2677719	Zolg JW, Plitt JR, Chen GX, Palmer S: Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol Biochem Parasitol. 1989 Oct;36(3):253-62.
9554869	McKie JH, Douglas KT, Chan C, Roser SA, Yates R, Read M, Hyde JE, Dascombe MJ, Yuthavong Y, Sirawaraporn W: Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria. J Med Chem. 1998 Apr 23;41(9):1367-70.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
M22159

# Drug_Target_2_GenBank_ID_Protein:
160260

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
Not Available

# Drug_Target_2_Gene_Sequence:
>1827 bp
ATGATGGAACAAGTCTGCGACGTTTTCGATATTTATGCCATATGTGCATGTTGTAAGGTT
GAAAGCAAAAATGAGGGGAAAAAAAATGAGGTTTTTAATAACTACACATTTAGAGGTCTA
GGAAATAAAGGAGTATTACCATGGAAATGTAATTCCCTAGATATGAAATATTTTCGTGCA
GTTACAACATATGTGAATGAATCAAAATATGAAAAATTGAAATATAAGAGATGTAAATAT
TTAAACAAAGAAACTGTGGATAATGTAAATGATATGCCTAATTCTAAAAAATTACAAAAT
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAATTTAAACCTTTAAGC
AATAGGATAAATGTTATATTGTCTAGAACCTTAAAAAAAGAAGATTTTGATGAAGATGTT
TATATCATTAACAAAGTTGAAGATCTAATAGTTTTACTTGGGAAATTAAATTACTATAAA
TGTTTTATTATAGGAGGTTCCGTTGTTTATCAAGAATTTTTAGAAAAGAAATTAATAAAA
AAAATATATTTTACTAGAATAAATAGTACATATGAATGTGATGTATTTTTTCCAGAAATA
AATGAAAATGAGTATCAAATTATTTCTGTTAGCGATGTATATACTAGTAACAATACAACA
TTGGATTTTATCATTTATAAGAAAACGAATAATAAAATGTTAAATGAACAAAATTGTATA
AAAGGAGAAGAAAAAAATAATGATATGCCTTTAAAGAATGATGACAAAGATACATGTCAT
ATGAAAAAATTAACAGAATTTTACAAAAATGTAGACAAATATAAAATTAATTATGAAAAT
GATGATGATGATGAAGAAGAAGATGATTTTGTTTATTTTAATTTTAATAAAGAAAAAGAA
GAGAAAAATAAAAATTCTATACATCCAAATGATTTTCAAATATATAATAGCTTGAAATAT
AAATATCATCCTGAATACCAATATTTAAATATTATTTATGATATTATGATGAATGGAAAT
AAACAAAGTGATCGAACGGGAGTAGGTGTTTTAAGTAAATTCGGATATATTATGAAATTT
GATTTAAGTCAATATTTCCCATTATTAACTACGAAGAAATTATTTTTAAGAGGAATTATT
GAAGAATTGCTTTGGTTTATTAGAGGAGAAACAAATGGTAATACGTTGTTAAATAAGAAT
GTAAGGATATGGGAAGCTAATGGTACTAGGGAATTTTTAGATAATAGAAAATTATTTCAT
AGAGAAGTTAACGATTTAGGACCTATTTATGGTTTTCAATGGAGACATTTCGGTGCTGAA
TATACAAATATGTATGATAATTATGAAAATAAAGGAGTGGATCAATTAAAAAATATAATA
AATTTAATTAAAAATGATCCTACAAGTAGAAGAATTCTTTTGTGTGCATGGAATGTAAAA
GATCTTGACCAAATGGCATTACCTCCTTGTCATATTTTATGTCAGTTTTATGTTTTCGAT
GGGAAATTATCATGTATTATGTATCAAAGATCATGTGATTTAGGGCTAGGAGTACCTTTT
AATATTGCTTCTTATTCTATTTTTACTCATATGATTGCACAAGTCTGTAATTTGCAACCT
GCGCAGTTCATACACGTTTTAGGAAATGCACATGTTTATAATAATCACATTGATAGTTTA
AAAATTCAACTTAACAGAATACCCTATCCATTCCCAACACTTAAATTAAATCCAGATATT
AAAAATATTGAAGATTTTACAATTTCGGATTTTACAATACAAAATTATGTTCATCATGAA
AAAATTTCAATGGATATGGCTGCTTAA

# Drug_Target_2_General_Function:
Nucleotide transport and metabolism

# Drug_Target_2_General_References:
2663650	Snewin VA, England SM, Sims PF, Hyde JE: Characterisation of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine. Gene. 1989 Mar 15;76(1):41-52.
2677719	Zolg JW, Plitt JR, Chen GX, Palmer S: Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol Biochem Parasitol. 1989 Oct;36(3):253-62.
2825189	Bzik DJ, Li WB, Horii T, Inselburg J: Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc Natl Acad Sci U S A. 1987 Dec;84(23):8360-4.
3057499	Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ: Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9109-13.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
620

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
71818

# Drug_Target_2_Name:
Bifunctional dihydrofolate reductase-thymidylate synthase

# Drug_Target_2_Number_of_Residues:
608

# Drug_Target_2_PDB_ID:
1J3K

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00186	DHFR_1
PF00303	Thymidylat_synt

# Drug_Target_2_Protein_Sequence:
>Bifunctional dihydrofolate reductase-thymidylate synthase
MMEQVCDVFDIYAICACCKVESKNEGKKNEVFNNYTFRGLGNKGVLPWKCNSLDMKYFRA
VTTYVNESKYEKLKYKRCKYLNKETVDNVNDMPNSKKLQNVVVMGRTNWESIPKKFKPLS
NRINVILSRTLKKEDFDEDVYIINKVEDLIVLLGKLNYYKCFIIGGSVVYQEFLEKKLIK
KIYFTRINSTYECDVFFPEINENEYQIISVSDVYTSNNTTLDFIIYKKTNNKMLNEQNCI
KGEEKNNDMPLKNDDKDTCHMKKLTEFYKNVDKYKINYENDDDDEEEDDFVYFNFNKEKE
EKNKNSIHPNDFQIYNSLKYKYHPEYQYLNIIYDIMMNGNKQSDRTGVGVLSKFGYIMKF
DLSQYFPLLTTKKLFLRGIIEELLWFIRGETNGNTLLNKNVRIWEANGTREFLDNRKLFH
REVNDLGPIYGFQWRHFGAEYTNMYDNYENKGVDQLKNIINLIKNDPTSRRILLCAWNVK
DLDQMALPPCHILCQFYVFDGKLSCIMYQRSCDLGLGVPFNIASYSIFTHMIAQVCNLQP
AQFIHVLGNAHVYNNHIDSLKIQLNRIPYPFPTLKLNPDIKNIEDFTISDFTIQNYVHHE
KISMDMAA

# Drug_Target_2_Reaction:
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P13922

# Drug_Target_2_SwissProt_Name:
DRTS_PLAFK

# Drug_Target_2_Synonyms:
DHFR-TS

# Drug_Target_2_Theoretical_pI:
7.41

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB00205
